| Equillium Continues Graft-Versus-Host Disease Trial, Pauses 2 Others | Sarah de Crescenzo | 03/27/20 | San Diego |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections | Sarah de Crescenzo | 03/26/20 | San Diego |
| FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch | Frank Vinluan | 03/26/20 | New York |
| Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel | Sarah de Crescenzo | 03/26/20 | Boston |
| Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown | Sarah de Crescenzo | 03/23/20 | National |
| UCSD, 5 Diagnostic Makers Partner to Ramp COVID-19 Testing Capacity | Sarah de Crescenzo | 03/20/20 | San Diego |
| Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More | Sarah de Crescenzo | 03/20/20 | National |
| As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future | Editors | 03/19/20 | Boston |
| How San Diego Biotech Leaders Are Adapting to Coronavirus Concerns | Sarah de Crescenzo | 03/19/20 | San Diego |
| UC San Diego Health Develops COVID-19 Test, Begins Testing Patients | Sarah de Crescenzo | 03/14/20 | San Diego |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Xcelerating Life Sciences San Diego Will Be Delivered Digitally | Editors | 03/11/20 | National |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects | Sarah de Crescenzo | 03/05/20 | San Diego |
| National Xconomy Awards Now Accepting Nominations for the Best in Biotech | Editors | 03/03/20 | National |
| ORIC Pharma Plans IPO to Test Therapies for Drug-Resistant Cancers | Sarah de Crescenzo | 03/02/20 | San Francisco |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data | Sarah de Crescenzo | 02/26/20 | San Diego |
| NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data | Sarah de Crescenzo | 02/24/20 | San Francisco |
| Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug | Frank Vinluan | 02/23/20 | National |
| Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More | Sarah de Crescenzo | 02/21/20 | National |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
| Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks | Frank Vinluan | 02/13/20 | National |
| Ligand’s Icagen Deal Brings Neuro, CF Assets Plus Partnering Potential | Frank Vinluan | 02/12/20 | San Diego |
| Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. | Frank Vinluan | 02/11/20 | National |
| Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s | Frank Vinluan | 02/10/20 | National |
| Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More | Sarah de Crescenzo | 02/07/20 | National |
| Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial | Sarah de Crescenzo | 02/06/20 | San Diego |
| Early Bird Sale Ending for San Diego’s Xcelerating Life Sciences Conference | Editors | 02/06/20 | National |
